文献速递脑血管病神经重症与神经感染

年龄≤70岁患者接受静脉格列本脲治疗大半球梗死的长期结局:GAMES-RP II期研究的探索性分析

Long-Term Outcomes in Patients Aged ≤70 Years With Intravenous Glyburide From the Phase II GAMES-RP Study of Large Hemispheric Infarction: An Exploratory Analysis.
PubMed 文献 · Stroke · 2018-05-22

本研究为GAMES-RP II期随机双盲安慰剂对照试验的探索性分析,纳入年龄≤70岁、符合方案标准的大半球梗死患者,静脉格列本脲组35例、安慰剂组30例。格列本脲组全因死亡率较低(生存风险比0.34,P=0.04),90天改良Rankin量表有获益趋势(比值比2.31,P=0.07),Barthel指数和EuroQol五维度量表显示显著治疗效应,基质金属蛋白酶-9水平和脑中线移位均较低。

要点

  • 年龄≤70岁大半球梗死患者接受静脉格列本脲治疗,全因死亡率较低(生存风险比0.34,P=0.04)。
  • 90天改良Rankin量表显示格列本脲有获益趋势(比值比2.31,P=0.07),未达统计学显著。
  • 格列本脲组基质金属蛋白酶-9水平和脑中线移位均低于安慰剂组(P<0.001)。

核心结论

  • 在这项探索性分析中,年龄≤70岁的大半球梗死患者接受静脉格列本脲急性治疗后生存率改善。

研究设计与样本

  • GAMES-RP为前瞻性、双盲、随机、安慰剂对照II期临床试验,共纳入86例年龄18至80岁、来自18个中心的大半球梗死患者(基线弥散加权成像体积82-300 cm3),症状发作10小时内随机分组。
  • 本探索性分析纳入年龄≤70岁且符合方案标准的患者,静脉格列本脲组35例、安慰剂组30例,格列本脲或安慰剂按1:1比例给药。
  • 分析指标包括90天和12个月死亡率、功能结局(改良Rankin量表、Barthel指数)、生活质量(EuroQol五维度量表)、血脑屏障损伤(基质金属蛋白酶-9)和脑水肿(脑中线移位)。

主要发现

  • 年龄≤70岁接受静脉格列本脲治疗的患者在所有时间点死亡率均较低(生存风险比0.34,P=0.04)。
  • 年龄校正后,90天改良Rankin量表显示格列本脲组有获益趋势(比值比2.31,P=0.07)。
  • 采用广义估计方程对90天、6个月和12个月重复测量分析显示,静脉格列本脲对Barthel指数有显著治疗效应(P=0.03),对EuroQol五维度量表有显著治疗效应(P=0.05)。
  • 与安慰剂组相比,格列本脲组血浆基质金属蛋白酶-9水平较低(189 vs 376 ng/mL,P<0.001),脑中线移位较小(4.7 vs 9 mm,P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: We aimed to determine whether subjects aged ≤70 years who were treated with intravenous glyburide (RP-1127; BIIB093; glibenclamide) would have better long-term outcomes than those who received placebo. METHODS: GAMES-RP (Glyburide Advantage in Malignant Edema and Stroke-Remedy Pharmaceuticals) was a prospective, double-blind, randomized, placebo-controlled phase 2 clinical trial. Eighty-six participants, aged 18 to 80 years, who presented to 18 centers with large hemispheric infarction (baseline diffusion-weighted imaging volumes, 82-300 cm3) randomized within 10 hours of symptom onset were enrolled. In the current exploratory analysis, we included participants aged ≤70 years treated with intravenous glyburide (n=35) or placebo (n=30) who met per-protocol criteria. Intravenous glyburide or placebo was administered in a 1:1 ratio. We analyzed 90-day and 12-month mortality, functional outcome (modified Rankin Scale, Barthel Index), and quality of life (EuroQol group 5-dimension). Additional outcomes assessed included blood-brain barrier injury (MMP-9 [matrix metalloproteinase 9]) and cerebral edema (brain midline shift). RESULTS: Participants ≤70 years of age treated with intravenous glyburide had lower mortality at all time points (log-rank for survival hazards ratio, 0.34; P=0.04). After adjustment for age, the difference in functional outcome (modified Rankin Scale) demonstrated a trend toward benefit for intravenous glyburide-treated subjects at 90 days (odds ratio, 2.31; P=0.07). Repeated measures analysis at 90 days, 6 months, and 12 months using generalized estimating equations showed a significant treatment effect of intravenous glyburide on the Barthel Index (P=0.03) and EuroQol group 5-dimension (P=0.05). Participants treated with intravenous glyburide had lower plasma levels of MMP-9 (189 versus 376 ng/mL; P<0.001) and decreased midline shift (4.7 versus 9 mm; P<0.001) compared with participants who received placebo. CONCLUSIONS: In this exploratory analysis, participants ≤70 years of age with large hemispheric infarction have improved survival after acute therapy with intravenous glyburide. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01794182.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Sheth KN, Petersen NH, Cheung K, et al. Long-Term Outcomes in Patients Aged ≤70 Years With Intravenous Glyburide From the Phase II GAMES-RP Study of Large Hemispheric Infarction: An Exploratory Analysis. Stroke. 2018. PMID: 29789393. doi:10.1161/STROKEAHA.117.020365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。